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a b s t r a c t
The typical characteristics of mesenchymal stem cells (MSCs) can be affected by inﬂammatory
microenvironment; however, the exact contribution of HTLV-1 to MSC dysfunction remains to be
elucidated. In this study, we demonstrated that MSC cell surface molecules VCAM-1 and ICAM-1 are
upregulated by contact with HTLV-1, and HLA-DR was most highly expressed in MSCs co-cultured with
MT2 cells. The expression levels of VCAM-1 and HLA-DR were increased in MSCs cultured in the presence
of PBMCs isolated from HTLV-1-infected symptomatic individuals compared with those cultured with
cells from asymptomatic infected individuals or healthy subjects. HTLV-1 does not impair the MSC
differentiation process into osteocytes and adipocytes. In addition, MSCs were efﬁciently infected with
HTLV-1 in vitro through direct contact with HTLV-1-infected cells; however, cell-free virus particles were
not capable of causing infection. In summary, HTLV-1 can alter MSC function, and this mechanism may
contribute to the pathogenesis of this viral infection.
& 2013 Published by Elsevier Inc.
Background
Human T lymphotropic virus type 1 (HTLV-1) is a human
retrovirus that is associated with two major diseases known as
adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated
myelopathy/tropical spastic paraparesis (HAM/TSP). Only a small
fraction (0.25% to 5%) of HTLV-1-infected individuals develops
HAM/TSP, whereas 2% to 5% develop ATLL (Osame et al., 1986;
Uchiyama, 1997), but other inﬂammatory disorders, including
myositis, peripheral neuropathy, uveitis, arthritis, Sjögren syn-
drome, and alveolitis, have also been related to HTLV-1 infection
(Oh and Jacobson, 2008). HAM/TSP is characterized as a chronic
progressive inﬂammatory disease that initiates as an inﬂammatory
disorder and progresses to a chronic long-term degenerative
disease (Araújo et al., 1995). This inﬂammatory response can be
characterized by the presence of HTLV-1-speciﬁc antibodies and
the inﬁltration of T lymphocytes into the peripheral blood and
cerebrospinal ﬂuid (CSF). In response to the presence of HTLV-1,
CNS inﬁltrating lymphocytes and resident cell populations trigger
the release of cytotoxins, particularly pro-inﬂammatory cytokines,
such as tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ),
to cause an inﬂammatory response (Umehara et al., 1993, 1994;
Jacobson et al., 1992).
It is still unclear why only a small subset of HTLV-1-infected
individuals develops clinical diseases whereas the majority
remains HTLV-1 asymptomatic carriers (HACs). Previous studies
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have suggested that this result is due to a genetic susceptibility
associated with deregulated immune responses and an increased
viral or proviral load (Nagai et al., 1998).
Mesenchymal stromal cells (MSCs) are multipotent precursor
cells with numerous immunomodulatory properties that have been
isolated from multiple tissues, such as the bone marrow (BM),
adipose tissue, umbilical cord blood, dental pulp, and the connective
tissue of almost all organs (Friedenstein et al., 1976; da Silva
Meirelles et al., 2006). The minimum criteria for MSC deﬁnition
include plastic adherence, the surface expression of CD105 (endoglin,
SH2), CD73 (ecto-5′-nucleotidase), and CD90 (Thy1), the absence of
hematopoietic markers, such as CD45, CD34, CD14, CD11b, CD79α,
CD19, and HLA-DR, and their in vitro differentiation into chondro-
genic, adipogenic, and osteogenic cells (Dominici et al., 2006). These
stromal cells have remarkable immunomodulatory and regenerative
properties due to the secretion of anti-inﬂammatory proteins and
suppress the activity of various immune cells, such as alloantigen-
activated T and B lymphocytes. In contrast, it has been reported that
the functionality and ability of MSCs to inhibit immune cells can be
modulated by inﬂammatory mediators released from activated
immune cells, such as IFN-γ, IL1β, and TNF-α. MSCs may provide a
balance of immune responses by acquiring a pro-inﬂammatory or an
anti-inﬂammatory capacity depending on the stimulus and the
physiological conditions of the organism (Waterman et al., 2010;
Auletta et al., 2012).
Due to the biological importance of MSCs, studies have inves-
tigated the interaction between MSCs and viruses and have
demonstrated that MSCs can be cell targets for several infections
(Marandin et al., 1995; Scadden et al., 1990; Smirnov et al., 2007;
Choudhary et al., 2011). For example, human immunodeﬁciency
virus (HIV-1) is able to infect bone marrow-derived MSCs, and this
infection affects MSC biology, impairing their clonogenic potential,
cell differentiation, and phenotype (Wang et al., 2002; Cotter et al.,
2008, 2011, 2007). Human vessel wall-derived MSCs are also suscep-
tible to HIV, and this susceptibility is connected with a dysregulation
of their survival and differentiation potential (Gibellini et al., 2011).
Human cytomegalovirus (CMV) infects MSCs, thereby changing their
structure and function, and this process alters their morphological
character and impairs their process of differentiation. Therefore, MSCs
may be considered a site of CMV latency and reactivation (Smirnov
et al., 2007; Wei et al., 2011). Other studies have shown that MSCs are
susceptible to herpes simplex virus type-1 (HSV-1) and that this
infection induces a cytopathic effect with viral productive replication
(Choudhary et al., 2011).
Although MSC are considered a target of several viral infec-
tions, there are no reports in the literature on the susceptibility of
MSCs to HTLV infection, and the biological effects of HTLV-1 on
MSCs are unknown. Therefore, in this study, we demonstrate that
HTLV-1 is able to infect human bone-marrow MSCs in vitro and
induce alterations to the MSC phenotype. The interaction between
HTLV-1 and MSC contributes to the current understanding of
HTLV-1 dissemination and persistence and provides new informa-
tion on HTLV-1 tropism and associated diseases.
Results
HTLV-1 exposition modiﬁes MSC morphology
Morphology and ultrastructural analyses were performed to
identify alterations in MSCs induced by HTLV-1. For this purpose,
three distinct culture conditions were evaluated: (1) MSCs in the
presence of 100 ng of cell-free virus, (2) MSCs co-cultured with MT2
cells in a transwell system, and (3) MSCs co-cultured with MT2 cells
subjected to irradiation (60,000 Gy). As the control culture, MSCs
were grown in the same medium in the absence of virus. The light
microscope analyses showed that the MSC morphology was not
affected by exposure to HTLV-1. The cells maintained their ﬁbro-
blastoid-like, spindle-shaped morphology, similar to the control
MSCs (Fig. 1A and B). However, the ultrastructural analysis of MSCs
cultured in the presence of HTLV-1 showed morphological changes,
including an increase in the number of intracellular vesicle struc-
tures, compared with the control MSC (Fig. 1C and D). In addition,
Fig. 1. Characterization of MSCs exposed to HTLV-1. (A and B) Morphological analysis by light microscopy of (A) control bone marrow (BM)-mesenchymal stromal cells
(MSCs) and (B) MSCs exposed to HTLV. The scale bars represent 100 μm. (C–F) Ultrastructural analysis by transmission electron microscopy of (C) control MSCs and (D) MSCs
exposed to HTLV with numerous intracellular vesicles (indicated by arrows); (E) HTLV-1 particles from MT2 cells are observed in the extracellular space (arrows), and
(F) HTLV-1 virus particles are found in close association with MSCs (arrows). Scale bars¼1 μm.
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we observed the release of HTLV-1 virions by MT2 cells (Fig. 1E) co-
cultured in close proximity to MSCs (Fig. 1F).
MSCs exposed to HTLV-1 showed alterations in the
immunophenotypic properties
To investigate the effect of HTLV-1 exposure on the physiological
features of MSCs, we analyzed the expression level of MSC surface
molecules by ﬂow cytometry. The analysis revealed that the
expression of adhesion molecules, such as VCAM-1 (CD106) and
ICAM-1 (CD54), were signiﬁcantly increased in MSCs exposed to
HTLV-1 (po0.01) compared with the controls. The higher expres-
sion levels of CD106 and CD54 observed in MSCs cultured with
HTLV-1-irradiated cells and in MSCs cultured with cell-free HTLV-1
were similar (Fig. 2A and B). We also observed that the expression
of aminopeptidase N (CD13) was 1.3-fold lower in MSCs cultured
with irradiated MT2 cells (p¼0.007; Fig. 2C). The expression of the
MHC class II cell surface receptor (HLA-DR) protein was 7.7-fold
higher in the same cell population (p¼0.0006). It is important to
note that this difference was observed only between MSCs that had
direct contact with HTLV-1-infected-cells and MSCs cultured in the
absence of HTLV-1 (Fig. 2C and D). Signiﬁcant differences were also
observed in the expression of the NGF receptor p75NTR protein
(CD271), which was reduced (2.5-fold) in MSCs cultured with cell-
free concentrated HTLV-1 (p¼0.0247) compared with MSC control
cultures (Fig. 2E). The expression levels of HLA-ABC, CD73, endoglin
(CD105), and CD45 were similar (p40.05) in MSC control cultures
and MSCs exposed to HTLV-1 (Supplementary material 1 A–D).
The variations observed in the expression of the surface
molecules CD106, CD54, and CD271 were also evaluated by qPCR.
The transwell culture resulted in an increase of 5.3- to 2.3-fold in
the mRNA expression levels of CD106 and CD54 on MSCs
(Supplementary material 2A and 2B). The most signiﬁcant increase
was obtained in the presence of cell-free HTLV-1 and through the
direct contact of infected cells and MSCs (6.8- to 18-fold). We also
observed that the CD271 gene expression was downregulated
(4.5-fold) in MSCs cultured in the presence of HTLV-1 compared
with MSCs cultured without HTLV-1 (Supplementary material 2C).
MSC immunophenotypic characteristics are altered by PBMCs from
HTLV individuals
Because the group of HTLV-1-infected individuals is composed
of both asymptomatic and symptomatic individuals, we examined
Fig. 2. Effect of HTLV-1 on MSC surface molecule expression. MSCs were cultured for 18 h under different growing conditions: control bone marrow (BM)-mesenchymal
stromal cells (MSCs), MSCs cultured with MT2 cells using a transwell system (MSCþtrans), MSCs cultured with cell-free HTLV-1 particles (MSCþvirus), and MSCs cultured in
the presence of irradiated MT2 cells (MSCþMT2). The data are presented as the means7SEM of the percentage of cells stained with (A) anti-CD106, (B) anti-CD54, (C) anti-
CD13, (D) anti-HLA-DR, and (E) anti-CD271, as evaluated by ﬂow cytometry. The results were obtained from at least three independent experiments and evaluated using a
one-tail Mann–Whitney t test. The asterisks denote signiﬁcant differences compared with the MSC control culture (*po0.05, **po0.01, and ***po0.001).
Fig. 3. Immunophenotypic proﬁle of MSCs co-cultured with PBMCs from HTLV-1-infected individuals. MSCs were cultivated with PBMCs isolated from HTLV-1-infected
symptomatic individuals (human T lymphotropic virus type 1 (HTLV-1) associated myelopathy/tropical spastic paraparesis; HAM/TSP), asymptomatic HTLV-1 carriers (HAC),
and healthy subjects (control) using a transwell system. The data are presented as the means7SEM of the percentage of cells stained with (A) anti-CD106, (B) anti-CD54,
(C) anti-CD271, and (D) anti-HLA-DR antibodies, as evaluated by ﬂow cytometry. The results were obtained from three independent experiments. We used the Mann–
Whitney one-tail t test. *po0.05 compared with healthy subjects (control).
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whether the PBMCs isolated from these individuals can modulate
the expression of adhesion molecules (CD106 and CD54), HLA-DR,
and CD271 in MSCs. All of the individuals included in this assay
exhibited a CD4þ/CD8þ ratio within the normal limits. As shown
in Fig. 3, CD106 was overexpressed (10-fold) in the MSCs cultured
with PBMCs from the HTLV-1 symptomatic group compared with
MSCs cultured with cells obtained from healthy subjects or
asymptomatic infected individuals (p¼0.0189; Fig. 3A). The
expression of HLA-DR was 2.6-fold higher in MSCs cultured with
PBMCs isolated from HTLV-1 symptomatic individuals compared
with that obtained in MSCs cultured with cells from healthy
subjects or asymptomatic infected individuals (p¼0.0175;
Fig. 3B). The CD54 and CD271 expression levels showed no
differences between MSCs cultured with PBMCs from HTLV-1-
infected individuals or from healthy subjects (Data not shown).
HTLV-1 exposure does not alter the MSC differentiation potential
We also evaluated the effect of HTLV-1 on the MSC ability to
differentiate into adipocytes and osteocytes. For this purpose,
MSCs were cultivated with virus particles (using a transwell
system or cell-free concentrated HTLV-1) or directly co-cultured
with irradiated MT2 cells for a period of 18 h. After this period, the
MSCs were differentiated into adipocytes and osteocytes for 22
days using the appropriate induction culture medium. In response
to adipogenic differentiation, we observed changes in the cell
morphology and the formation of lipid vacuoles, as visualized
through Sudan II/Scarlet staining, regardless of the presence or
absence of HTLV-1 (Fig. 4C, E, G, and I). The analysis of the
peroxisome proliferator-activated receptor gamma (PPAR-γ) gene
expression showed a 70-fold increase in MSCs subjected to
Fig. 4. Adipogenic and osteogenic differentiation of MSCs exposed to HTLV-1. (I) Morphologic analyses of bone marrow (BM)-mesenchymal stromal cells (MSCs) cultured for
18 h in the presence or absence of HTLV-1. MSCs were stained by Sudan II/Scarlet (C, E, G, and I) and the von Kossa method (D, F, H, and J) to evaluate the adipogenic and
osteogenic differentiation potential, respectively. (A and B) Control MSCs cultured on standard medium; (C and D) control MSCs; (E and F) MSCs cultured with MT2 cells
using a transwell system; (G and H) MSCs cultured with cell-free HTLV-1 particles; and (I and J) MSCs cultured in the presence of irradiated MT2 cells. The arrows indicate
lipid vacuoles (C, E, G, and I) and mineralization nodules (D, F, H, and J). The scale bars represent 20 μm. (II) PPARγ gene expression in MSCs during adipogenic differentiation,
as determined by qRT-PCR. (III) Level of Runx2 gene expression during osteoblastic differentiation, as determined by qRT-PCR. Control mesenchymal stromal cells (MSCs),
MSCs cultured with MT2 cells in a transwell system (MSCþtrans), MSCs cultured with cell-free HTLV-1 particles (MSCþvirus), and MSCs cultured in the presence of
irradiated MT2 cells (MSCþMT2). ADI: adipogenic induction; WD: without differentiation induction; OSTEO: osteogenic induction. The data are reported using expression
relative units (ERU), and the results are represented as the means7SEM (n¼4 per group). The asterisks denote signiﬁcant differences relative to the undifferentiated control
(*pr0.05).
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adipogenic differentiation compared to non-induced MSC. How-
ever, the comparison of MSCs cultured in the presence of HTLV-1
and the MSC control culture revealed no signiﬁcant difference in
the mRNA expression of the PPAR-γ gene (Fig. 4II).
To further evaluate the effect of HTLV-1 infection on osteogen-
esis, we compared MSC control cultures and MSCs exposed to
HTLV-1. The osteogenic differentiation potential of MSCs was not
altered by HTLV-1, and the analyses of calcium deposition and
mineralization of the extracellular matrix indicated that there
were no signiﬁcant differences in osteogenic differentiation poten-
tial of the studied samples (Fig. 4D, F, H, and J). The analysis of
the mRNA expression of the runt-related transcription factor 2
(RUNX2) gene revealed that this gene was 2.4-fold overexpressed
in MSCs undergoing differentiation into osteocytes than in non-
differentiated MSC. However, the RUNX2 expression level in MSCs
that had contact with HTLV-1 was similar to that found in the MSC
control culture, indicating that HTLV-1 does not alter the differ-
entiation potential of MSCs into osteocytes (Fig. 4III). These results
suggest that HTLV-1 does not modify the differentiation potential
of MSCs into adipocytes and osteocytes.
MSCs are susceptible to HTLV-1 infection
Because HTLV-1 infects various cell types, we questioned whether
MSCs are susceptible to HTLV-1 infection in vitro. First, we evaluated
the expression of genes encoding proteins for HTLV-1 receptors, such
as GLUT1, HSPG, and NRP1. These gene products are involved in the
initial interaction between the cell and the virus and are required for
HTLV-1 infection in different cell types. MSCs isolated from the BM of
healthy individuals exhibited a GLUT1 gene expression level similar
to that obtained in CD4þ T cells from healthy individuals and CD4þ T
cells from HTLV-1-infected individuals; however, the HSPG gene was
overexpressed (37-fold) in MSCs compared with CD4þ T cells from
HTLV-1 individuals (p¼0.0022). The expression level of the NRP1
gene was 11-fold higher in CD4þ T cells from HTLV-1 individuals
compared with CD4þ T cells from healthy individuals (p¼0.004);
however, NRP-1 presented higher expression levels in MSCs (Fig. 5).
To evaluate whether the contact of HTLV-1 with MSCs allows
the efﬁcient infection of MSCs, we investigated the presence of
HTLV-1 provirus in DNA samples extracted from MSCs exposed to
HTLV-1. We observed the ampliﬁcation of the HTLV-1 Tax gene
by PCR only in MSCs that were cultured with irradiated MT2
cells. No ampliﬁcation was observed in MSCs grown with cell-free
HTLV-1 particles and in the MSC control cultures (Fig. 6I). The
results obtained by PCR corroborated the analyses of the expres-
sion levels of HTLV-1 proteins. As shown in Fig. 6II (E and F), MSCs
cultured with MT2 cells are positive for the HTLV-1 p19 protein, as
evidenced by confocal microscopy analyses (Fig. 6IIE and 6IIF). No
evidence of the p19 speciﬁc signal was observed in the control
cultures (Fig. 6IIH and III). The HTLV-1 Tax regulatory protein was
also detected in MSCs co-cultured with MT2 cells by ﬂow cyto-
metry, which suggests that HTLV-1 results in productive infection
and viral replication in MSCs (Fig. 6IV).
Discussion
HTLV-1 is a retrovirus that primarily infects T cells and is able to
establish lifelong latency in its host. Although the great majority of
HTLV-1-infected individuals remain asymptomatic, a minor group
of patients develops one of two main disorders, namely HAM/TSP
and ATLL, and other clinical manifestations, such as uveitis,
arthritis, and infectious dermatitis (Oh and Jacobson, 2008;
Yoshida et al., 1984; LaGrenade et al., 1990; Mariette et al.,
2000). Various factors, such as the proviral load and the effective-
ness of the immune response, are considered important factors
that determine the risk of developing clinical diseases (Manns
et al., 1999; Montanheiro et al., 2005).
In contrast, the immunomodulation properties of MSCs can
exert an effective inhibitory effect on the function of immune cells
and thus provide an interesting therapeutic tool for the treatment
of degenerative disorders, as well as inﬂammatory and autoi-
mmune diseases (Di Nicola et al., 2002; Bartholomew et al., 2002).
Several studies have reported that the role of MSCs can be
modulated by inﬂammatory mediators released from activated
immune cells (Waterman et al., 2010; Auletta et al., 2012). Thus,
the exposure of MSCs to an infectious or inﬂammatory micro-
environment could alter their functions and change their differ-
entiation potential and interaction with immune cells.
In this study, we present data that demonstrate the inﬂuence of
HTLV-1 on the biological and functional features of BM-derived
MSCs. Our results showed that MSCs exposed to HTLV-1 display
distinct characteristics from those of MSCs cultured under control
conditions. For example, contact with HTLV-1 resulted in the
accumulation of vesicles in the cytosol of MSCs, and this phenom-
enon is similar to that observed when HTLV-1 infects HeLa cells,
Jurkat cells, and human primary PBMCs (autophagic vacuoles).
This accumulation of autophagosomes is induced by the HTLV-1
Tax protein and beneﬁts virus replication (Tang et al., 2013).
Surface molecules, such as ICAM-1, VCAM-1, and HLA-DR, were
found to be upregulated in MSCs after contact with HTLV-1. In
addition, PBMCs isolated from HTLV-1 symptomatic individuals
were also able to modulate the expression of VCAM1 and HLA-DR
in MSCs, even without direct cell contact.
The cell surface glycoproteins ICAM-1 and VCAM-1 are mem-
bers of the immunoglobulin superfamily that are closely related to
the processes of recognition, interaction, and adhesion. The
expression of ICAM-1 and VCAM-1 ﬁrst occurs in endothelial cells
and immune system cells; however, previous studies have described
that MSCs may produce large amount of chemokines and adhesion
molecules after stimulation with inﬂammatory cytokines (Ren et al.,
2008, 2010). Moreover, the serum of HAM/TSP individuals shows a
higher concentration of pro-inﬂammatory cytokines, such as TNF-α,
IL-6 and IFN-γ, compared with that of asymptomatic individuals,
and these cytokines can modulate the MSC adhesion molecules
(Starling et al., 2013). Other studies have shown that MSC activity
can be modulated differently depending on the environment. Viral
infections are stimuli that can enhance the immunosuppressive
capacity promoted by MSCs due to an increase in the expression of
Fig. 5. Gene expression of HTLV-1 receptors in different cell types. Quantiﬁcation
by real-time PCR of the mRNA levels of GLUT1, HSPG, and NRP-1 in CD4þ T cells and
MSCs isolated from healthy individuals and HTLV-1-infected individuals. The data
are reported as expression relative units (ERU) and represent the means7SEM of
triplicate experiments. We used a one-tail Mann–Whitney t test, and the asterisks
denote signiﬁcant differences compared with CD4þ T cells (*po0.05 and
**po0.01).
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adhesion molecules (ICAM-1 and VCAM-1) (Ren et al., 2010).
Therefore, MSCs exposed to HTLV-1 should also induce a differ-
entiated immunosuppressive effect on T lymphocytes because
ICAM-1 and VCAM-1 expression modulate the immune regulatory
properties of MSCs.
According to the literature, a signiﬁcant increase in the expres-
sion levels of ICAM-1 (CD54) and LFA-3 (CD58) has been described
in MSCs in response to CMV infection, and this increase is
associated with a higher adherence of hematopoietic cells to
CMV-infected MSCs (Smirnov et al., 2007). Previous studies have
demonstrated that, in HTLV-1 infection, ICAM-1 and LFA-1 are
modulated in T cells (Barnard et al., 2005), and these interactions
are important for cell fusion and the dissemination of HTLV-1,
thereby allowing an improvement of the cell-cell contact, the
polarization of the cytoskeleton, and the formation of a viral
synapse (Igakura et al., 2003). However, the increased expression
of adhesion molecules (ICAM-1 and VCAM-1) in MSCs exposed to
HTLV-1 suggests that the contact between infected cells and MSCs
is favored and may also promote the HTLV-1 infection of MSCs and
BM resident cells.
With respect to the expression of HLA-DR, some researchers
have shown that the expression of HLA-DR in MSCs depends on
the IFN-γ concentration. Upon exposure to antigens, the initial
doses of IFN-γ induce the expression of MHC-II molecules and
Fig. 6. HTLV-1 infection in MSCs. (I) Human β-globin and HTLV-1 tax gene ampliﬁcation by PCR. The results were obtained from three independent experiments. Control
mesenchymal stromal cells (MSC01, MSC02, and MSC03), MSCs cultured with cell-free HTLV-1 particles (MSC01þvirus, MSC02þvirus, and MSC03þvirus), and MSCs
cultured in the presence of irradiated MT2 cells (MSC01þMT2, MSC01þMT2, and MSC01þMT2), MT2 DNA (positive control), and no template control (NTC). (II)
Representative immunoﬂuorescence staining of mesenchymal stromal cells. (A) MSCs co-cultured with MT2 cells were stained with DAPI (blue) and (B) anti-CD73 (red);
(C) overlap of DAPI (blue) and anti-CD73 (red) staining. MSCs co-cultured with MT2 cells were stained with (D) DAPI (blue) and (E) anti-CD19 (green); (F) overlap of DAPI
(blue) and anti-CD19 (green) staining. The nucleus of control MSCs were stained with (G) DAPI (blue) and (H) anti-CD19 (green); (I) overlap of DAPI (blue) and anti-CD19
(green) staining. The scale bars represent 10 μm. (III and IV) Representative ﬂow cytometry dot plots of MSCs co-cultured with MT2 cells. (III) Isotype-matched control
antibodies. (IV) The dots in the upper right quadrant of the ﬂow plot represent cells that coexpress CD73 and the HTLV-1 tax protein (8%).
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thereby facilitate the antigen presenting properties of MSCs.
However, at high levels of IFN-γ, the MHC-II expression is down-
regulated, which causes a loss in the ability of MSCs to act as
antigen presenting cells (APCs) (Stagg et al., 2006; Romieu-Mourez
et al., 2007).
Other typical surface molecules that are commonly used in the
characterization of MSC, such as CD271 and CD13, were also
modulated by HTLV-1 contact. However, further studies should
be conducted to understand the differences in the expression of
these molecules in MSCs exposed to HTLV-1 because no studies
have reported the involvement of CD271 in virus infection and
CD13 expression is considered important in other infections, e.g.,
in CMV infection, CD13 is reported to act as a receptor (Soderberg
et al., 1993).
The functional capacity of MSCs to differentiate into adipocytes and
osteocytes was not altered in MSCs exposed to HTLV-1, and this
ﬁnding was conﬁrmed by the analysis of the gene expression levels of
PPARγ and RUNX-2. Previous reports have described that HTLV-1 may
be linked to bone alteration by increasing the population of active
osteoclasts in ATLL patients (Kiyokawa et al., 1987). This change is
likely not related to HTLV-1-exposed MSCs because we observed that
HTLV-1 did not impair the osteogenic differentiation potential of this
cell population. It is believed that the alterations observed in the
osteoclasts of ATLL cells and HTLV-1-infected T cells maintained in
culture may arise due to the overexpression and secretion of speciﬁc
cytokines that stimulate the proliferation of osteoclast precursors and
promote their differentiation (Tendler et al., 1991).
Other authors who assessed the MSC differentiation potential
during HIV infection showed that the p55-gag viral protein affects
osteogenesis by reducing calcium deposition and the expression
and activity levels of RUNX-2. However, the cell lipid levels and
PPARγ activity were increased by HIV proteins during adipogenic
MSC differentiation (Cotter et al., 2008, 2011, 2007). Experiments
performed with sera from high-viral-load HIV-infected individuals
induced a proadipogenic phenotype, as evidenced by the increased
adipocyte formation and the expression of PPARγ (Cotter et al.,
2011). HIV infection has also been found to affect the proliferation
and osteogenic differentiation of MSCs isolated from Tg26 HIV-1
mice, which suggests that the infection progressively causes
damage to MSC functionality (Cheng et al., 2013).
Our results also provide the ﬁrst demonstration that the
interaction between HTLV-1 and BM-derived MSCs leads to their
infection in vitro. In fact, the presence of HTLV-1 integrated
provirus was evidenced only in MSCs that had direct contact with
an infected cell and not with cell-free virions, which shows that
direct contact with an infected cell is efﬁcient for the virus
infection of MSCs. These ﬁndings support the hypothesis that the
main transmission route for HTLV-1 infection ﬁrst occurs through
cell-to-cell contact because cell-free virions are very poorly
infectious in vitro (Donegan et al., 1994). However, in other cell
types, such as DCs, efﬁcient and productive infection has been
observed with cell-free HTLV-1 (Jones et al., 2008).
The existence of HTLV-1-infected cells in the BM had been explored
in in vivo studies on ATLL patients, and the results have shown that
HTLV-1 DNA is detected in BM mononuclear cells but not in
hematopoietic stem cells (CD34þ) (Nagafuji et al., 1993). An extensive
latent infection in the BM of patients with HTLV-1 has also been
demonstrated; however, the phenotype of HTLV-1-infected BM cells is
unclear (Jacobson et al., 1997). We suggest the biological existence of
HTLV-1-infected MSCs in the BM of HTLV-1-infected individuals;
however, further studies are necessary to detect the productive
infection of MSCs isolated from HTLV-1-infected individuals.
Others studies have previously been performed to elucidate the
susceptibility of MSCs to virus infection and the possible consequences
of the contact of MSCs with infectious agents. Herpes virus (HSV-1)
was found to be able to infect MSCs in vitro and induces a cytopathic
effect, as evidenced by signs of swelling and detachment from walls
(Sundin et al., 2006). Recently, Avanzi et al. (2013) demonstrated that
fetal membrane (FM) derived-MSCs (FM-MSCs) are fully permissive to
infection with herpes simplex virus 1 and 2 (HSV-1 and HSV-2),
varicella zoster virus (VZV), and human cytomegalovirus (HCMV) but
not with Epstein-Barr virus (EBV) and human herpes virus 6, 7, and 8
(HHV-6, 7, and 8). Although these viruses are capable of entering FM-
MSCs, transient and limited viral gene expression occurs (Avanzi et al.,
2013).
Conclusion
In conclusion, we have shown that HTLV-1 modiﬁes important
MSC characteristics, such as the formation of intracellular vesicle
structures and the expression of the surface molecules ICAM-1,
VCAM-1, and HLA-DR. However, the MSC ability to differentiate into
adipocytes and osteocytes was not affected by HTLV-1. In addition,
MSCs were found to be susceptible to HTLV-1 infection in vitro, and
this ﬁnding was supported by the hypothesis that, as part of the
regular immune surveillance process, HTLV-1-infected CD4þ and
CD8þ T cells are able to trafﬁc during primary infection and viral
latency into the BM, where cell-to-cell contact over a prolonged
period of time can lead to progressive HTLV-1 BM invasion and
probable infection of BM resident cells (Grant et al., 2002). Under-
standing the biological mechanisms involved during HTLV-1 infec-
tion and knowing the target cells and the possible routes of HTLV-1
spread in the body may aid the development of an appropriate and
effective management strategy for this infection that improves the
quality of life of HTLV-1-infected individuals.
Methods
HTLV-1-seropositive individuals
HTLV-1-seropositive individuals were diagnosed from blood-
donor candidates of the Regional Blood Center of Ribeirão Preto.
Samples were also collected from HTLV-1-infected individuals
belonging to the Neurology Department of the University Hospital,
São Paulo, Brazil. The diagnosis of HTLV-1/2 infection was estab-
lished by an antibody screening of serum/plasma samples using an
enzyme immunoassay (EIA; ORTHO HTLV-1/2 Ab-capture ELISA test
system, Ortho Clinical Diagnostics, Inc., Raritan, N, USA) followed by
PCR conﬁrmation using ampliﬁcation primers for the tax and LTR
regions of HTLV-1 and the LTR and pX regions of HTLV-2 according
to previously described protocols (Pinto et al., 2012). The HTLV-1
group consisted of seven individuals classiﬁed as healthy asympto-
matic HTLV-1 carriers (HAC; 57.1% females, 42.9% males; mean
age¼46.2 years) and six individuals with HAM/TSP (83.3% females,
16.7% males; mean age¼51.5 years). The mean HTLV-1 proviral load
was 2190.8 copies/105 cells for HAC individuals and 7214.9 for HAM/
TSP individuals. The healthy control group consisted of seven
randomly selected blood donors from the same geographical region
as the HTLV-1-positive individuals described above, and these had a
mean age of 44.7 years (85.7% females, 14.3% males). This study was
approved by the Institutional Ethics Committee at the General
Hospital of the Faculty of Medicine in Ribeirão Preto, University of
São Paulo, Brazil (Process number 12462/2010). All of the patients
enrolled in this study signed a written informed consent form.
Isolation, culture, and characterization of the cells
Peripheral blood mononuclear cells (PBMCs). PBMCs were
separated from the whole blood using Ficoll-Paque™ PLUS
(GE Healthcare Biosciences, Uppland, Sweden) according to the
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manufacturer’s instructions. The T cells phenotypic analysis for
CD3þ , CD8þ , CD45þ , and CD4þ was performed by ﬂow cytometry
(BD Multitest™, BD Biosciences, CA, USA). Immunomagnetic cell
separation was performed to obtain CD4þ T cells (CD4 MicroBeads
MACs Miltenyi Biotec, CA, USA).
MSC isolation. Approximately 10 mL of human bone marrow
aspirates were collected from healthy donors. The mononuclear
cells were separated by Ficoll-Paque™ PLUS (GE Healthcare
Biosciences, Uppland, Sweden), and the MSCs were isolated by
plastic adherence and cultured at a concentration of 2–4
105 cells/mL in 25-cm2 ﬂasks (Corning, NY, USA) with alpha
minimum essential medium (α-MEM) (Gibco, NY, USA) supple-
mented with 15% heat-inactivated standard fetal bovine serum
(HyClone, UT, USA), 2 mM L-glutamine (Gibco, Grand Island, NY,
USA), and 1% penicillin–streptomycin (Gibco, NY, USA). The non-
adherent T cells were removed after 72 h, and the formation
of colonies was observed after 3 to 4 days. The plastic-adherent
MSCs at passages 3–5 were used in the experiments. The cultured
MSCs were immunophenotypically characterized using the follow-
ing monoclonal antibodies: CD45-FITC (ﬂuorescein isothiocya-
nate), CD31-FITC, HLA-DR-FITC, CD73-PE (phycoerythrin), CD146-
FITC, CD90-PE, CD29-APC (allophycocyanin), CD44-FITC, CD13-PE,
CD49e-PE, HLA-ABC-PE, CD34-APC, CD14-PE, CD54-PE, CD166-PE,
and CD105-PerCP (peridinin chlorophyll protein complex) (BD
Biosciences, CA, USA). The adipogenic, osteogenic, and chondro-
genic MSC differentiation potential were evaluated as
described below.
Cell lines. MT2 cells (HTLV-1-infected cell line) were cultured
in RPMI (Gibco, NY, USA) supplemented with 10% fetal bovine
serum and 1% penicillin–streptomycin (Gibco, NY, USA). All of the
cultures were maintained in a humidiﬁed atmosphere of 5% CO2 at
37 1C.
Virus infection and co-culture assay
The HTLV-1 concentration was determined according to the
following protocol. MT2 cells were cultured (1107) in complete
RPMI medium for 24 h. The viral supernatant was collected,
ﬁltered through a 45-μm ﬁlter (Millipore, MA, USA), and ultra-
centrifuged at 10,000g for 2 h. The concentrated virus was quanti-
ﬁed through p19 enzyme immunoassay (EIA) (ZeptoMetrix
Corporation, NY, USA) according to the manufacturer's instructions
and stored at 80 1C. The ability of HTLV-1 to infect MSCs was
examined using concentrated virus and co-culture assays. Human
MSCs (2.5103) at passages 3–5 were seeded into individual wells
of a six-well culture plates for 24 h. Concentrated HTLV-1 (100 ng)
was added to the MSC culture and maintained for 18 h. For the co-
culture assay, MSCs were cultured in complete RPMI medium at
37 1C for 18 h with MT2 cells irradiated with 60,000 Gy at a ratio of
1:1 or with MT2 cells in a transwell system (Greiner Bio-one, NC,
USA). As a control, we maintained cells in the same medium
without addition of the virus. The experiments were repeated at
least three times, and the results were calculated as the means7
SEM of triplicates.
Electron microscopy
MSCs co-cultured with MT2 cells for 18 h were ﬁxed with 2.0%
glutaraldehyde and 2% paraformaldehyde in 0.1 M (pH 7.2) caco-
dylate buffer supplemented with 5 mM MgCl2, 5 mM CaCl2, and
0.1 M sucrose. The ﬁlters were washed in cacodylate buffer and
postﬁxed for 1 h at room temperature in 1% osmium tetroxide
solution. The samples were washed three times in water and
incubated in 0.5% uracil acetate. The cells were dehydrated in an
ethanol gradient (from 25 to 100%) and embedded into epoxy
resin at 60 1C for 48 h. After washing in propylene oxide, ultrathin
sections were cut using a Leica Ultracut S microtome. The sections
were then examined using a JEOL JEM-100 CX II electron
microscope.
Immunocytochemistry assay
Immunocytochemistry was performed to conﬁrm the HTLV-1
infection of MSCs. MSCs co-cultured with MT2 cells (2104) or
under control conditions were seeded on glass coverslips (Gold-
Lab, SP, Brazil) in 24-well plates (Corning, NY, USA) and incubated
until the cells reached 80% conﬂuence. The cells were ﬁxed in 4%
paraformaldehyde (Merck, NJ, USA) for 20 min at room tempera-
ture, washed three times with PBS, and then permeabilized with
0.2% Triton X-100 (Sigma-Aldrich, MO, USA) for 1 h at room
temperature. The cells were blocked for 1 h with 5% bovine serum
albumin (BSA) and 2% goat serum diluted in PBS. The samples
were separately incubated with primary anti-HTLV-1 p19 anti-
bodies (Abcam, MA, USA) and CD73 (BD Pharmingen, CA, USA) at
room temperature overnight. The secondary antibody used was
Alexa Fluor 488 mouse antibody (Invitrogen, CA, USA). The nuclei
were stained with DAPI (Vysis, IL, USA). The cells were visualized
separately using a confocal laser scanning microscope (CLSM)
(LSM 710; Carl Zeiss, Germany) with 20x and 63x objective lenses
and a numerical aperture of 1.4. An argon 488-nm laser was used
to excite the ﬂuorochrome of the secondary antibodies, and the
emission was measured at 525 nm. The visualization of the light
scattering for each excitation wavelength was recorded in the
multitracking mode using separate detection channels. The image
analysis was performed using the ZEN2008 software (Carl Zeiss,
Germany). The control and test images were captured using
identical settings.
Flow cytometry analysis
The cultured MSCs were immunophenotypically characterized
by ﬂow cytometry using the following monoclonal antibodies:
CD106 (VCAM1, vascular cell adhesion molecule 1)-PE, CD54
(ICAM-1, type I transmembrane protein)-PE, CD13-APC, HLA-DR
(major histocompatibility complex, class II)-PE, CD271 (NGFR,
nerve growth factor receptor)-PE, HLA-ABC-PE, CD73 (NT5E,
5-nucleotidase, ecto)-PE, CD105 (ENG, endoglin)-PerCP, and CD45
(Leukocyte common antigen)-FITC (BD Biosciences, CA, USA).
For the intracellular detection of tax, the cells were ﬁxed in 1%
paraformaldehyde (Sigma-Aldrich, MO, USA), permeabilized with
1% Tween 20, and stained with a speciﬁc antibody (kindly
provided by Dr. Yuetsu Tanaka, University of the Ryukyus, Oki-
nawa, Japan). For the analysis of the surface epitope by FACS, the
cells were incubated with ﬂuorescence-conjugated antibodies
(1 μg per 106 cells) at room temperature for 30 min. After washing
twice with 1X PBS, the cells were suspended in PBS and analyzed
using a FACScalibur ﬂow cytometer (BD Biosciences, CA, USA). Ten
thousand events were acquired and analyzed using the CellQuest
software (BD Biosciences, CA, USA). Nonspeciﬁc IgG of the corre-
sponding class served as a negative control.
MSC differentiation into adipocytes and osteocytes
The adipogenic and osteogenic differentiation of MSCs was
obtained as described previously (Castilho-Fernandes et al., 2011).
In brief, the differentiation was induced after incubation of the
cells with speciﬁc differentiation media for adipocytes (α-MEM
(Gibco-Invitrogen, CA, USA) supplemented with 15% FBS (Thermo
Scientiﬁc HyClone, UT, USA), 1 mM dexamethasone (Dex; Sigma-
Aldrich, MO, USA), 2.5 mg/mL insulin, and 0.5 mM isobutylmethyl-
xanthine (Sigma-Aldrich, MO, USA)) and for osteocytes (α-MEM
(Gibco-Invitrogen, CA, USA) supplemented with 7.5% FBS (Thermo
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Scientiﬁc HyClone, UT, USA), 0.1 mM Dex (Sigma-Aldrich, MO,
USA), 20 mM ascorbic acid, and 1 M β-glycerophosphate (Sigma-
Aldrich, MO, USA)). The media were replaced every three days
over a period of 22 days, and the cells were then ﬁxed and stained
through the von Kossa method (for calcium deposition) with
Sudan II and Scarlet stains (for accumulation of fat). The control
cells were maintained in standard α-MEM (Gibco, Invitrogen, CA,
USA) with 7.5% fetal bovine serum (Thermo Scientiﬁc HyClone, UT,
USA) over the same period. The cells were analyzed using an
AxioScope 2.0 Zeiss microscope equipped with an AxioCam HR
(Carl Zeiss, Jena, Germany) and by real-time PCR for the gene
expression.
Quantitative real-time PCR (qRT-PCR)
The total cell RNA was extracted using an RNeasy mini kit
(Qiagen, North Rhine-Westphalia, Germany) according to manu-
facturer´s instructions and stored at 80 1C. The quantity and
quality of the RNA were assessed by spectrophotometry using a
Nanodrop instrument (Thermo Fisher Scientiﬁc, NJ, USA). The
complementary DNA (cDNA) was synthesized from 1 μg of total
RNA using a high-capacity cDNA archive kit (Applied Biosystems,
CA, USA). The cDNA was diluted 10 times in nuclease-free water
and was used in each real-time PCR reaction. The SYBRs Green
PCR mix (Applied Biosystems, CA, USA) was used to determine the
gene expression of HTLV-1 receptors using the following primers:
NRP1F, 5′-CCTGAATGTTCCCAGAACTACACAA-3′; NRP1R, 5′-CAA-
CATCAGGGAATCCATCCC-3′; HSPG2F, 5′-TGGACACATTCGTACCT-
TTCTGA-3′; HSPG2R, 5′-ACTCCGACTCCAGCGTGTCT-3′; GLUT1F,
5′-atggagcca gcagcaagaa-3′; GLUT1R, 5′-agggaccagagcgtggtgag-3′.
We also evaluated the gene expression of PPARγ using the
following primers: PPARF, 5′-TCCCGCTGACCAAAGCAAG-3′; PPARR,
5′-CAGGGGGGTGATGTG TTTGA-3′. The endogenous controls were
human actin beta (ACTB; ACTBF, 5′-GCCCTGAGGCACTCTTCCA-3′;
ACTBR, 5′-CCAGGGCAGTGATCTCCTTCT-3′) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH; GAPDHF, 5′-GCCTCAAGATCAT-
CAGCAATGC-3′; GAPDHR, 5′-CATGGACTGTGGTCATGAGTCCT-3′).
The single-product ampliﬁcation was conﬁrmed by the post-
melting curve.
The quantitative RT-PCR was performed using TaqMan™ assays
for the tax and env HTLV-1 genes (speciﬁc probe FAM labeled),
RUNX2 (Hs00231692_m1), CD106 (Hs00174239_m1), CD54
(Hs00164932_m1), and CD271 (Hs00609977_m1; Applied Biosys-
tems, CA, USA). The reaction was performed in a ﬁnal volume of
15 μL for 40 cycles under universal cycling conditions (40 cycles of
95 1C for 15 s and 60 1C for 1 min) in an ABI Prism 7500 sequence
detection system (Applied Biosystems, CA, USA). The results were
normalized using the geometric mean of the endogenous genes
GAPDH, ACTB, and B2 microglobulin (B2M). Duplicate samples
were measured and averaged. The results are reported using
expression relative units (Albesiano et al., 2003). The HTLV-I
proviral load was determined using the pol HTLV-1 and
ACTB genes.
Statistical analysis
The assays were conducted in at least triplicate. To evaluate the
differences between MSCs cultured under control conditions and
MSCs exposed to HTLV-1, we used the Mann–Whitney t test. The
results are expressed as the means7SEM. The statistical analysis
was performed using GraphPad Prism (version 5.0; La Jolla, CA,
USA), and differences were considered statistically signiﬁcant if
npo0.05, nn po0.01, and nnn po0.001.
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